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I-iuman umbilical vein cndotheliel cells (HlJVECs) in primary culture produced and sccrcted cndothclin I (ET-I) actively. Spccitic binding OT 
[lzsI]ET-l to these cells was not detectable because of Ihe saturation of ET receptors with endogenously produced ET-I. However, addition of 
phosphoramidon, an inhibitor of ET-convertingenyme, to the medium reduced the production of ET-I and thus the receptors on HUVECs were 
made available for exogcnously added [‘z51]ET-l, Binding studies using phosphoramidon-treated HUVECs indicated the existence of a non- 
isopcptide-sclcctive type (BT,) of ET receptor iith a Kd ol’l7 pM. This rcccptor is thought to be involved in ET-induced vasodilation in an autocrinc 
manner in viva, 
Bndothelin; Endothelial ceil; Receptor; Vasodilation 
1. INTRODUCTION 
Endothelin, now known as ET-l, was first purified 
from the culture medium of porcine endothelial cells 
and is the most potent and longest acting constrictor of 
vascular and non-vascular smooth muscle cells [l]. Sub- 
sequently, ET-l has been shown to be a member of a 
family consisting of three isopeptides (ET-l, -2, and -3), 
which exhibit distinct pharmacological actions [2]. 
Their actions are mediated by two receptor subtypes, 
i.e. ET-l- and ET-Zselective ETA and non-isopeptide- 
selective ET” [3-G]. 
ETs stimulate endothelial cells (ECs) to secrete two 
well-characterized vasodilator substances, prostacyclin 
[7,8] and endothelium-derived relaxing factor [8,9]. ET- 
1 and ET-2 are much more potent than ET-3 in their 
vasoconstrictive effects, whereas the three ETs are 
almost equipotent in their vasodilatory effects. It is, 
therefore, likely that ET receptor on ECs are of the ETa 
subtype. However, the nature of ET receptors on ECs 
still remains controversial. Emori et al. [lo] reported 
that the ET receptors in cultured bovine aortic ECs are 
of ETc (ET-3-specific) subtype (but not ET,, subtype) 
based on the observation that [L251]ET-3 binding is not 
displaced by unlabeled ET-l. Takayanagi et al. [ 111, on 
the other hand, suggested the presence of ETa receptor 
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on ETs from the finding that specific binding sites for 
l%labeled [Gluq sarafotoxin S6b, a ligand relatively 
specific for ETa receptor, are detected in membranes of 
endothelium-containing rat thoracic aorta, but become 
almost undetectable after removal of the endothelium. 
Furthermore, Ogawa et al. [6] detected significant ex- 
pression of ETa receptor mRNA in human umbilical 
vein endothelial cells (HUVECs). 
In this paper, we show that ET receptors on 
HUVECs in primary culture are saturated with en- 
dopnous ET-l and unable to bind exogenously added 
[i~51]ET-l. When the production of endogenous ET-1 is 
inhibited by treating the cells with phosphoramidon, an 
inhibitor of ET-converting enzyme [12], the receptors 
become detectable by binding assay with [“‘I]ETs. 
Using this strategy we have- been able to demonstrate 
that the receptors on HUVECs are of the ETB (non- 
isopeptide-selective) subtype. 
2. MATERIALS AND METHODS 
HUVECs (2nd passage) were purchased from Kurabo (Osaka, 
Japan) and cultured on 6mwell plates at 37°C in a CO1 incubator (5% 
CO1, 9S% air) as-previously reported [13]. After reaching confluency, 
various concentrations of phosphoramidon (Peptide Institute Inc., 
Osaka, Japan) were added with fresh media every 24 h for a further 
2 days. Experiments were performed on the 3rd day after reaching 
confluency. All cells used in these experiments wet-c subculturcd 3 
limes. 
Phosphoramidon-treated and untreated HUVECs were washed 
with 20 mM HEPES (pH 7.4), containing I40 mM NaCI, 4 mM KCI. 
1 m-M i&HP&, i mhi iviBQ, l mivi CnCtz, 10 mM o-Ju~se and 
0.05% bovine serum albumin (HBSS). The cells were incubated in 
HBSS with SO pM [lz51]ET-I or[1251)ET-3 (-74TBqlmmol. Amcrsham) 
Publisfwd by Elsovhr Scimcr Prtbiishcrs 6. V. 79 
Volume 298, number I FEBS LETTERS February 1992 
to obtain total binding. Non-specilic binding was determined in the 
presence of 100 nM unlabeled ET-I or ET-3. Specific binding was 
defined as total binding minus non-spefilic binding. After incubation 
at 37°C for I II, the reaction wasstopped by aspiration oflhe reaction 
buffer. The cells were washed twice with ice-cold HBSS and solubilizcd 
in IN NaOH. The cell-associated radioactivity was measured in a 
Wallac-1470 Wizard autogamma cower (Pharmacia), 
2.3. D~wrtrtitwriott o/-ET-I atui big ET-/ it1 rkc crrhure rtxhm 
ET-l and big ET-I were purified from the culture medium of 
HUVECs by adsorption onto un Amprcp ethyl C2 minicolumn 
(Amcrsham), followed by reversed-phase high-performance liquid 
chromatography [12], Fractions corresponding 10 ET-I and big ET-I 
were collected, evaporated and used for radioimmunoassay (RIA) 
with an [‘zSI]ET RIA kit (Amersham). 
ET-I was also determined by a receptor binding assay using porcine 
lung membranes. Porcine lung was homogenized with a Kinematica 
Polytron homogenizer (Lucern, Switzerland) three times at top speed 
for each 30 s in 9 vols of ice-cold 0.25 M sucrose solution containing 
20 mM Tris-#Cl (PI-I 7.4). After ccntrirugation of the homogenate at 
I,000 x g for 10 min al 4’C, the supernatant wds centrifuged again at 
20,000 x g for 20 min. The resulting pellet was washed three times as 
described above and used as a membrane preparation. The membrane 
(10 $6 protein) was incubated with 10 pM [‘251]ET-3 in the presence 
of serial dilutions of the conditioned medium (<200 ~1) in a total 
volume of I ml of MBSS. After incubation at 37°C for I h. the 
membrane-associated radioactivity was recovered by centrifugation 
and counted. The calibration curve was obtained with known amounts 
of authentic ET- I, 
The ECs were identified by immunofluorescent s aining with mouse 
antibody against vector-VII I (Synbiotics Corp., USA), an endothelial 
marker protein, and fluorescein isothiocyanatu-labeled anti-mouse 
IgG antibody (Kirkegaard & Perry Labs. Inc., USA). The viability or 
ECs was examined by a dye exclusion test with 0.01% Trypsn blue, 
2.5. Ligk t microscopic radio-urrtogrftplt~ 
HUVECs cultured on slide-glass wells were incubated al 37°C for 
I h with 50 pM [“:‘I]ET-I or [“‘IlET- in the presence of absence or 
100 nM unlabeled ET-I or ET-3 as described above. Then, the cells 
were rinsed twice in HBSS and firred with 0.75% glutaraldehydc in 0. I 
M sodium phosphate (pH 7.5) for IO min. After dehydration in SO% 
ethanol for 15 min. slides were air-dried, dripped into Konica NR-M2 
emulsion and stored in the dark. After exposure for 20-35 days, the 
slides were developed with Konidol X for 6 min at 25°C and observed 
under a microscope. 
was approximately the same as the ET-I content ob- 
served when the cells were cultured in the absence of the 
inhibitor. These results indicated that phosphoramidon 
specifically inhibited the conversion of big ET-l to ET- 1 
catalyzed by ET-converting enzyme, as reported previ- 
ously [12,14]. However, the concentration of phosphor- 
amidon which inverted the ratio of ET-l/big ET-l, 
determined for HUVECs (4 mM) was much higher than 
that reported for bovine aortic ECs (3-10 PM) [14]. 
The phosphoramidon-induced ecrease in ET-I ac- 
cumulation was accompanied by the appearance of spe- 
cific binding sites for 50 pM [?]ET-I on HUVECs (3.3 
fmol/106 cells at 12 mM phosphoramidon). The extent 
of this appearance was dependent on the phosphor- 
amidon concentration used (Fig. 1). It was thus evident 
that in the absence of the inhibitor, the binding sites for 
ET-I were saturated with endogeneous ET-l actively 
,produced by HUVECs themselves and, therefore, no 
further binding of [l’SI]ET-I could occur. 
The decrease in ET-I content after phosphoramidon 
treatment was also confirmed by a receptor-binding 
assay using porcine lung membranes (Fig. 2); the media 
after 24-h culture of HUVECs in the presence or 
absence of 4 mM phosphoramidon inhibited the 
[lz51]ET-3 binding dose-dependently; the inhibition was 
more pronounced with the medium after culture with- 
out phosphoramidon. From the slopes of inhibition 
curves, the ET-l content in the medium was calculated 
to be 500 fmol/lO” cells without phosphoramidon and 
200 fmol/lO’ cells with 4 mM phosphoramidon. The 
ET-l contents determined by this method were about 
45% of those determined by RIA. The reason for this 
discrepancy is unclear, but the possibility exists that 
RIA overestimated ET-I because of the presence of 
degradation products of ET- 1 [15], which can be re- 
cognized by the antibodies but not by the ET receptor. 
3. RESULTS AND DISCUSSION 
As reported previously [12], HUVECs produced and 
secreted ET-1 activity when cultured in the absence of 
phosphoramidon; the ET-1 content in the 24-h condi- 
tioned medium was determined by RIA to be 1,000 
fmoVl0” cells. Under these conditions, practically no 
big ET- 1 was detected (c 10 fmol/ 10” cells) and specific 
binding of 50 pM [“SI]ET-l to the cells was negligible 
(co.1 fmol/106 cells). When the cells were cultured in the 
presence of 12 mM phosphoramidon, which did not 
affect the cell number, viability of morphology of 
HUVECs, the content of ET-1 in the 24-h conditioned 
medium decreased to 45C fmoI/lO” cells whcrc~s that of 
big ET-1 increased to 560 fmoV106 cells. The sum of 
ET-1 and big ET-l contents was almost constant at all 
the phosphoramidon concentrations tested (Fig. 1). and 
Phosphoremldon Added (M) 
Fig. 1. Et&ts of phosphoramidon, at various concentrations, on the 
contents of ET-l (A) and big ET-l (& in the cultured medium and 
the specific binding of 50 pM [‘x31]ET-I to HUVECs (0). Each point 
is the mean of triplicate determinations. 
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Fig. 2. Receptor binding assay for ET-l-like material in the culture 
medium of HUVECs. Shown is the displaccmcnt of IO pM [‘zsl]ET-3 
binding by increasing concentrations of ET-I in porcine lung 
membranes (0). The inset shows ihc displacement of ET-3 binding in 
porcine lung membranes by the indicalcd volumes of unconditioned 
(0. H) or HUVEC-conditioned culture medium (A. A). Data were 
obtained in the absence (n. A) or presence (m, A) of4 mM phosphor- 
amidon, Each point is the mean of lriplicutc determinations. 
Another possibility is that ET-l in the medium was 
partly trapped by unknown substances and, therefore, 
could not bind to the receptor. 
The cell number of HUVECs in the culture was un- 
changed by the addition of 4 mM phosphoramidon. 
More than 90% of cells were immunoreactive with anti- 
factor VIII antibodies both in the presence and absence 
of phosphoramidon (data not shown). Autora- 
diographs of HUVECs cultured with 4 mM phosphor- 
amidon, when incubated with radiolabeled ET-I or ET- 
3, showed densely associated specific labeling in more 
than 90% of the cells (Fig. 3A). The radioactive deposits 
in the phosphoramidon-treated cells decreased signifi- 
cantly by co-incubation with IO0 mM unlabeled ET-l 
or ET-3 (data not shown). However, the cells cultured 
in the absence of phosphoramidon exhibited no specific 
labeling even after incubation with 50 pM [“sI]ET-l or 
[‘z51]ET-3 (Fig. 3B). These results indicated that the 
appearance of binding sites for radiolabeled ET-l or 
ET-3 after phosphoramidon treatment was not due to 
selective growth of a minor population of non-endothe- 
lial cells. 
We then attempted to characterize this binding. The 
Scatchard plot of [“‘l]ET-I binding to HUVECs 
treated with 4 mM phosphoramidon (Fig. 4A) revealed 
a single component of high affinity binding sites for 
ET-l with a dissociation constant (K,,) of 17 pM and a 
maximum binding capacity (B,,,,) of 4.8 fmoll106 cells. 
With [lz51]ET-3 as ligand, almost the same K,, and S,,,,, 
values were obtained as those for [“51]ET-1. In competi- 
tive binding assays with 50 pM (“‘I]ET-I, unlabeled 
ET-I and ET-3 showed almost identical displacement 
curves with an I& of 100 pM (Fig. 4B), indicating that 
the non-isopcptide-selective type of ET receptor (ETs) 
Fig. 3. Autoradiogrums of HUVECs cultured in the presence (A) or absence (B) of 4 mM phosphoramidon aRer incubation with 50 pM [‘251]ET-l. 
This experiment was performed with HUVECs under a scmiconfiuent condition. Essentially identical autoradiograms were obtained with 
[1251]ET-3. (Upper panels) light field observation; (lower panels) dark field observation. Bar, 100 Pm. 
81 
Volume 298, number I FESS LETTERS February 1992 
1 - . .....’ . .,..,I .a . .-I 
0 1 2 3 4 5 46' 10"' lO"O 16 id8 Id' 
Bound gmoli 1 I( IO6 cells) Cold Llgand Added (M) 
Fig. 4. (A) Scatchard analysis of the specific binding oT[‘~~I]ET-I to HUVECs cultured in the presence of4 mM phosphoramidon. (B) Competitive 
binding of 50 pM [“‘IlET- to HUVECs cultured in the presence of 4 mM phorphoramidon by unlabeled ET-I (01 and ET-3 (a). Results are 
expressed as percentages of the specific binding. Values are the means of triplicate determinations. 
is responsible for the binding of ETs to HUVECs. Big 
ET-l, up to 10 PM, did not significantly displace the 
[1z51]ET-l binding (data not shown). 
The Kd value for the endothelial ET” receptor (17 
pM) was lower than that for the ET,, receptor (58 PM) 
determined in A-10 cells derived from rat aortic smooth 
muscle. This is in good agreement with pharmacological 
observations that vasodilation can be induced by 
smaller amounts of ETs as compared with vasoconstric- 
tion [9]. The specific binding sites for 50 pM [‘“‘l]ET-1 
(3.3 fmol/106 cells) obtained when the cells were treated 
with 12 mM phosphoramidon was about I *S-fold that 
determined for the cells treated with 4 mM phosphor- 
amidon (2.1 fmoY106 cells) (Fig. 1). Since the ETI, re- 
ceptor on HUVECs was still partly occupied by en- 
dogenous ET-l even at the inhibitor concentration of 12 
mM, the number of ETB receptor expressed on 
HUVECs is calculated to be >5,000 sites/cell, which is 
comparable to the number of ETA receptor on A-10 
cells (2 1,000 sites/cell) (unpublished data). 
It can thus be concluded that HUVECs actively pro- 
duce and secrete ET-l and simultaneously express ETIl 
receptor as the major population, indicating that the 
receptor is an autocrine one. Cultured ECs from rat 
brain microvessels have been reported to possess ET 
receptors [16,17]. However, they are not involved in 
autocrinr functions, because these ECs are unable to 
produce ETs. 
In preliminary experiments we found that 100 nM 
ET-1 or ET-3 stimulated the release of prostacyclin 
from phosphoramidon-treated HUVECs but not from 
the untreated cells, suggesting that the endothelial ETB 
receptor is involved in vasodilation as postulated previ- 
ously [7,9]. Thus, it is likely that ET-l secreted from ECs 
82 
plays an important role as 2 local, autocrine vasomodu- 
lator by binding to ET, receptor on ECs themselves. In 
this function ET-I releases prostacyclin and endothe- 
hum-derived relaxing factor (NO) from ECs and thus 
attenuates the contraction mediated by smooth muscle 
ETA receptor. Such a natural, negative-feedback mecha- 
nism would balance the strong, sustained contractions 
invokved by ET-l. 
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